Sep 13, 2023 / 03:30PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Well, thanks, everybody, for joining us. I'm Terence Flynn from the U.S. biopharma analyst here at Morgan Stanley and we're very pleased to be hosting Vertex for this session. Today from the company, we have Reshma Kewalramani, who's President and CEO; and Charlie Wagner, who is CFO. Thank you both so much for being here. I appreciate the time today.
Before we get started, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Questions and Answers:
Terence C. Flynn - Morgan Stanley, Research Division - Equity AnalystWith out of the way, Reshma and I again, we had the opportunity to speak last night and again got a kind of a great overview of the company. And so I guess the question I wanted to start with was more one on strategy. Obviously, part of